Abstracts tagged "risk factors"

Abstract Number: 0896 • ACR Convergence 2024
Identification of Immune Pathways Regulated by a Non-Coding Variant at DNASE1L3/PXK/PDHB
Michelle Morency¹, Taehyeung Kim¹ and Peter Nigrovic², ¹Boston Children's Hospital, Boston, MA, ²Boston Children's Hospital, Brookline, MA
Background/Purpose: Rheumatoid arthritis (RA) is a prevalent autoimmune disease in which aberrant immune attacks on joints and other tissues leads to permanent and disabling injury.…
Abstract Number: 1501 • ACR Convergence 2024
Retrospective Cohort Study Identifying Pulmonary Complications in a Cohort of Patients with Systemic Lupus Erythematosus
Jessica Johnson¹, Chao Zhang² and Emily Littlejohn³, ¹Cleveland Clinic Lerner College of Medicine, Cleveland, OH, ²Cleveland Clinic, Cleveland Heights, OH, ³Cleveland Clinic, Cleveland, OH
Background/Purpose: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with multi organ involvement. One of the most common manifestations is pulmonary disease with a…
Abstract Number: 2324 • ACR Convergence 2024
Familial Aggregation in Psoriatic Arthritis: Phenotypic Differences in Patients with and Without First-degree Relatives with Psoriatic Disease
Catherine Howe¹, Weixi Chen², Jiyuan Hu², Kyra Chen³, Adamary Felipe³, Stephanie Eichman³, Margaret Coyle⁴, Eileen Lydon⁵, Andrea Neimann³, Soumya Reddy⁶, Jose Scher⁷ and Rebecca haberman⁸, ¹New York University Langone Medical Center, New York, NY, ²Division of Biostatistics, Department of Population Health, New York, NY, ³NYU Grossman School of Medicine, NYC, ⁴NYU Langone, Brooklyn, NY, ⁵NYU, New York, NY, ⁶NYU Grossman School of Medicine, New York, NY, ⁷New York University School of Medicine, New York, NY, ⁸NYU Langone Health, New York, NY
Background/Purpose: Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory disease of the joints, affecting up to a third of individuals with cutaneous psoriasis. Pathogenesis remains…
Abstract Number: 0487 • ACR Convergence 2024
The Triglyceride to HDL Ratio, a Surrogate Marker of Insulin Resistance, Predicts All Cause and Cardiovascular Mortality in Rheumatoid Arthritis
Jose Felix Restrepo Suarez¹, Carlos Lorenzo¹, Inmaculada Del rincon² and Agustin Escalante¹, ¹UT Health San Antonio, San Antonio, TX, ²UT Health San Antonio, San Antonio
Background/Purpose: The triglyceride to HDL cholesterol (TG/HDL) ratio, a recognized surrogate marker of insulin resistance, has emerged as a predictor of cardiovascular (CV) risk. However,…
Abstract Number: 0991 • ACR Convergence 2024
Comparing the Prevalence of Sarcoidosis in Canadian Rural, Urban, and Farming Populations
Varinder Hans¹, Don Voaklander¹, C. Allyson Jones² and Elaine Yacyshyn², ¹University of Alberta, Edmonton, Canada, ²University of Alberta, Edmonton, AB, Canada
Background/Purpose: Sarcoidosis is a granulomatous inflammatory response thought to be due to a dysregulated immune response to environmental antigens.1 The prevalence of sarcoidosis varies geographically.…
Abstract Number: 1509 • ACR Convergence 2024
Validation of a Score for the Prediction of Serious Infection in Patients with Systemic Lupus Erythematosus: Data from a Latin American Lupus Cohort
Rosana Quintana¹, Guillermo Pons-Estel², Karen Roberts³, Erika S. Palacios Santillan³, Íñigo Rúa-Figueroa⁴, José María Pego-Reigosa⁵, Pablo Ibañez⁶, Leonel Ariel Berbotto⁷, Maria Constanza Bertolaccini⁸, Marina Laura Micelli⁹, Cecilia Pisoni¹⁰, Vitalina De Souza Barbosa¹¹, Henrique de Ataíde Mariz¹², Francinne Machado Ribeiro¹³, Luciana Parente¹⁴, Emília Sato¹⁵, Milena Mimica Davet¹⁶, Gustavo Aroca Martínez¹⁷, Fabio Bonilla-Abadía¹⁸, Gerardo Quintana López¹⁹, Reyna E. Sánchez Briones²⁰, Mario Pérez Cristóbal²¹, Luis H. Silveira Torre²², Ignacio García De La Torre²³, Ivan Morales Avendaño²⁴, Pablo Gamez-Siller²⁵, Astrid Paats²⁶, Jorge N. Cieza Calderón²⁷, Andy Armando Mendoza Maldonado²⁸, Martin Rebella²⁹, Gonzalo Silveira³⁰, John Fredy Jaramillo³¹, Monica Sanchez³², Urbano Sbarigia³³, Ashley Orillion³⁴, Federico Zazzetti³⁵, Graciela Alarcon³⁶ and Bernardo Pons-Estel³⁷, and Grupo Latino Americano de Estudio del Lupus (GLADEL), ¹Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ²Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ROSARIO, Santa Fe, Argentina, ³Sección Reumatología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Department of Rheumatology, Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas GC, Spain, ⁵Galicia Health Service (SERGAS), Vigo, Spain, ⁶Servicio de Reumatología del HIGA San Martín, La Planta, Argentina, ⁷Unidad de Enfermedades Autoinmunes, Hospital Escuela Eva Perón, Granadero Baigorria, Argentina, Granadero Baigorria, Argentina, ⁸Servicio de Reumatologia - Hospital Angel C. Padilla, San Miguel de Tucumán, Argentina, ⁹Hospital General de Agudos Dr Ramos Mejia, CABA, Argentina, ¹⁰CEMIC, Buenos Aires, Argentina, ¹¹Hospital das Clínicas, Universidade Federal de Goias, Goias, Brazil, Goiânia, Brazil, ¹²Universidad Federal de Pernambuco, Recife, Brazil, ¹³Hospital Universitario Pedro Ernesto, UERJ, Rio De Janeiro, Brazil, Rio de Janeiro, Brazil, ¹⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ¹⁵Universidade Federal de Sao Paulo, São Paulo, SP, Brazil, ¹⁶Facultad de Medicina y Ciencia, Universidad, San Sebastián, Chile, ¹⁷Universidad Simón Bolivar, Barranquilla, Colombia, Barranquilla, Colombia, ¹⁸Fundación Valle del Lili, Unidad de Reumatología, Cali, Colombia, ¹⁹Universidad de Los Andes, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia, ²⁰División de Investigación en Salud, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, IMSS, CDMX, Mexico, ²¹Centro Médico Nacional Siglo XXI, CDMX, Mexico, IMMS, Mexico, ²²Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., Mexico City, Mexico, ²³Depto. de Inmunología y Reumatología; Centro de Estudios de Investigación Básica y Clínica, Guadalajara, Mexico, ²⁴Hospital Central Dr. Ignacio Morones Prieto, Potosi, Mexico, ²⁵Servicio de Reumatologia del Hospital Universitario, "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ²⁶Hospital de Clínicas I, Asunción, Paraguay, ²⁷Hospital Nacional Edgardo Rebagliatti Martins, Lima, Perú, Lima, Peru, ²⁸Hospital Cayetano Heredia. Universidad Peruana Cayetano Heredia, Lima, Peru, ²⁹Unidad Enfermedades Autoinmunes Sistemicas, Clinica Medica C-Hospital de Clinicas, UDELAR Montevideo, Montevideo, Uruguay, ³⁰Grupo de Investigación de EAIS y Reumatológicas, Montevideo, Uruguay, ³¹Centro de Referencia en Osteoporosis & Reumatología, Bogotá, Colombia, ³²Unidad Nefrologia,Hospital fernandez, CABA, Argentina, ³³Johnson & Johnson Innovative Medicine, Brussels, Belgium, ³⁴Johnson & Johnson Innovative Medicine, Spring House, PA, PA, ³⁵Johnson & Johnson Innovative Medicine, Horsham, PA, PA, ³⁶The University of Alabama at Birmingham, Oakland, CA, ³⁷Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at increased risk of serious infections, which in turn, are associated with morbidity and mortality. The Systemic…
Abstract Number: 2325 • ACR Convergence 2024
Predictors of Treatment Response and Continuation in Patients with Psoriatic Arthritis Initiating Secukinumab – Results from the EuroSpA Collaboration
Stylianos Georgiadis¹, Mikkel Ostergaard², Jette Heberg³, Zohra Faizy Ahmadzay⁴, Brigitte Michelsen⁵, Simon Horskjær Rasmussen⁶, Mehrdad Kazemi⁶, Johan Karlsson Wallman⁷, Tor Olofsson⁸, Bente Glintborg⁹, Anne Gitte Loft¹⁰, Isabel Castrejón¹¹, Ladislav Šenolt¹², Michael J. Nissen¹³, Burkhard Moeller¹⁴, Jorge Garcia¹⁵, Filipe Barcelos¹⁶, Ziga Rotar¹⁷, Katja Perdan-Pikmajer¹⁷, Catalin Codreanu¹⁸, Corina Mogosan¹⁸, Karin Laas¹⁹, Sigrid Vorobjov²⁰, Bjorn Gudbjornsson²¹, Gerdur Gröndal²¹, Dan Nordstrom²², Anna-Mari Hokkanen²³, Pawel Mielnik²⁴, Tore K. Kvien²⁵, Gökçe Kenar²⁶, Marleen Van De Sande²⁷, Merete Hetland²⁸ and Lykke Oernbjerg¹, ¹Rigshospitalet Glostrup, Glostrup, Hovedstaden, Denmark, ²Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, ³Rigshospitalet Glostrup, København V, Denmark, ⁴Rigshospitalet Glostrup and Copenhagen University, Glostrup, Denmark, ⁵Rigshospitalet Glostrup, Diakonhjemmet Hospital and Sørlandet Hospital, Copenhagen, Denmark, ⁶Rigshospitalet Glostrup, Glostrup, Denmark, ⁷Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Skane Lan, Sweden, ⁸Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Sweden, ⁹DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark, ¹⁰Aarhus University Hospital and Aarhus University, Horsens, Denmark, ¹¹Hospital General Universitario Gregorio Marañón and Complutense University of Madrid, Madrid, Spain, ¹²Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ¹³Geneva University Hospital, Geneva, Switzerland, ¹⁴Inselspital - University Hospital Bern, Bern, Switzerland, ¹⁵Clínica Médico Ourém, Ourém, Portugal, ¹⁶Universidade Nova de Lisboa, Instituto Português de Reumatologia and Hospital CUF Descobertas, Lisbon, Portugal, ¹⁷University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, ¹⁸University of Medicine and Pharmacy, Bucharest, Romania, ¹⁹East-Tallinn Central Hospital, Tallinn, Estonia, ²⁰National Institute for Health Development, Tallinn, Estonia, ²¹Landspitali University Hospital and University of Iceland, Reykjavik, Iceland, ²²Helsinki University Hospital, Helsinki, Finland, ²³Helsinki University and Helsinki University Hospital, Helsinki, Finland, ²⁴Helse Førde, Førde, Norway, ²⁵Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ²⁶Dokuz Eylul University School of Medicine, Izmir, Turkey, ²⁷Amsterdam Institute for Infection & Immunity and Reade and Amsterdam UMC, Amsterdam, Netherlands, ²⁸Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark
Background/Purpose: Several predictors of treatment response to tumour necrosis factor inhibitors (TNFi) in routine care have been reported in psoriatic arthritis (PsA). However, data on…
Abstract Number: 0033 • ACR Convergence 2024
Refined Autoantibody Profiles in RA Reveal That Primarily ACPAs Binding Non-glycine Citrulline Motifs Are Associated with Shared Epitope Alleles
Linda Mathsson-Alm¹, Helga Westerlind², Isabel Gehring³, Monika Hansson², Nasim Ghasemzadeh¹, Jessica Rojas-Restrepo³, Saedis Saevarsdottir⁴, Joseph Sexton⁵, Siri Lillegraven⁶, Espen Haavardsholm⁶, Merete Hetland⁷, Hilde Hammer⁸, Tore K. Kvien⁹, Bente Glintborg¹⁰, Leonid Padyukov², Johan Askling² and Caroline Grönwall², and the Danish Rheumatologic Biobank Study Group (the Biomarker Protocol), Swedish Rheumatology Quality Register Biobank Study Group (SRQb), ¹Thermo Fisher Scientific, Uppsala, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³Thermo Fisher Scientific, Freiburg, Germany, ⁴University of Iceland, Reykjavik, Iceland, ⁵Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ⁶Diakonhjemmet Hospital, Oslo, Norway, ⁷Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark, ⁸Diakonhjemmet Hospital, Oslo, Oslo, Norway, ⁹Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ¹⁰DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark
Background/Purpose: Carriage of HLA-DRB1 shared epitope (SE) alleles and a history of smoking, have been identified as the most prominent risk factors for development of…
Abstract Number: 0524 • ACR Convergence 2024
Evaluating Dose Reduction of Biologic Treatments in Rheumatoid Arthritis: Predicting Flares Using Clinical and Molecular Biomarkers
Laura Galindo Domínguez¹, Belen Acasuso², Vanesa Balboa-Barreiro³, Juan Fernández-Tajes², Juan Cañete⁴, Benjamin Fernández-Gutiérrez⁵, Isidoro González-Álvaro⁶, José L Pablos⁷, Carmen Bejerano-Herreria⁸, Maite Silva-Díaz⁹, Franciso javier De-Toro-Santos², Natividad Oreiro¹⁰ and francisco J Blanco¹¹, ¹Instituto de Investigacion Biomedica de A Coruña (INIBIC), A Coruña, Spain, ²Unidad de Investigacion Clinica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas., Investigation, A Coruña, Spain, A Coruña, Spain, ³Unidad de Epidemiología Clínica y Bioeostadística. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC)., A Coruña, Spain, ⁴Hospital Clinic an IDIBAPS, Barcelona, Spain, ⁵3Rheumatology Department, and Health Research Institute (IdISSC), Hospital Clínico San Carlos, Calle del Profesor Martín Lagos, s/n, 28040, Madrid, Spain., Rheumatology, Madrir, Spain, Madrid, Madrid, Spain, ⁶University Hospital La Princesa, Madrid, Madrid, Spain, ⁷Health ministry, Madrid, Madrid, Spain, ⁸Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁹Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, ¹⁰CHUAC, La Coruna, Galicia, Spain, ¹¹INIBIC-University of A Coruña, A Coruña, Spain
Background/Purpose: Reducing the dosage of biologic drugs in patients with rheumatoid arthritis (RA) who have achieved remission is a viable and necessary strategy. To identify…
Abstract Number: 0994 • ACR Convergence 2024
Association Between Cardiovascular Risk Factors and the Onset of Giant Cell Arteritis: A Systematic Review and Meta-analysis
François Barde¹, Lucas Pacoureau², Alexis Elbaz², Raphaele Seror³ and Yann Nguyen⁴, ¹Inserm, CESP, Paris, France, ²Inserm, CESP, Villejuif, France, ³Service de Rhumatologie, Hôpital Bicêtre, AP-HP, le Kremlin Bicetre, Ile-de-France, France, ⁴Université Paris Saclay, Clichy, Ile-de-France, France
Background/Purpose: Giant cell arteritis (GCA) predominantly affects people over 50 years of age, with a female predominance. Its pathophysiological mechanism is currently under debate. In…
Abstract Number: 1519 • ACR Convergence 2024
Incidence, Risk Factors, and Outcomes of Severe Lymphopenia in Systemic Lupus Erythematosus
Chunhui Chen¹, Emily Wu², Huong Do³ and Kyriakos Kirou³, ¹New York Presbyterian Queens, Flushing, NY, ²Hospital for Special Surgery, Rochester, NY, ³Hospital for Special Surgery, New York, NY
Background/Purpose: Lymphopenia is common in patients with systemic lupus erythematosus (SLE), occurring in 75-90% of cases over the disease course. It can result from SLE…
Abstract Number: 2369 • ACR Convergence 2024
Impact of Baseline Factors on Disease Progression and Apremilast Efficacy in Early Oligoarticular Psoriatic Arthritis
Philip Mease¹, Laura Coates², Alexis Ogdie³, Dafna Gladman⁴, Alen Zabotti⁵, Xenofon Baraliakos⁶, Cynthia Deignan⁷, Shauna Jardon⁷, Rebecca Wang⁷, Lichen Teng⁷ and Laure Gossec⁸, ¹Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ²University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, ³Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Azienda Sanitaria Universitaria del Friuli Centrale, Udine, Udine, Italy, ⁶Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁷Amgen Inc., Thousand Oaks, CA, ⁸Sorbonne Université, Paris, France
Background/Purpose: In the FOREMOST study of early oligoarticular psoriatic arthritis (PsA), fewer patients (pts) receiving apremilast (APR) progressed from ≤4 active joints (all joints; oligoarthritis)…
Abstract Number: 0049 • ACR Convergence 2024
Inflammatory Priming by Anti-MAA Antibodies in Rheumatoid Arthritis
Marcelo Afonso¹, Jitong Sun¹, Koji Sakuraba¹, Alexandra Circiumaru², Denis Lagutkin¹, Masa Filipovic¹, Anca Catrina¹, Caroline Grönwall¹, Aase Hensvold¹ and Bence Réthi¹, ¹Karolinska Institutet, Stockholm, Sweden, ²Division for Rheumatology, Karolinska Institutet; Center for Rheumatology, Academic Specialist Center, Stockholm region, Stockholm, Sweden
Background/Purpose: We have previously shown that autoantibodies targeting malondialdehyde-acetaldehyde protein adducts (anti-MAA) in rheumatoid arthritis (RA) patients boosted osteoclast differentiation and induced bone erosion in mice…
Abstract Number: 0627 • ACR Convergence 2024
Clinical Conditions Associated with Presence of a High-titer Antinuclear Antibody in Individuals Without Autoimmune Disease
Matthew Chung¹, John Shelley², John Still², Gul Karakoc³, Xiaodi Ruan⁴, Jonathan D. Mosley⁴, C. Michael Stein⁴ and Vivian K. Kawai⁴, ¹VU, Nashville, TN, ²VUMC, Nashville, TN, ³Vanderbilt University Medical Center, Mt. Pleasant, SC, ⁴Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Antinuclear antibodies (ANAs) are a diverse group of autoantibodies that are commonly present in SLE and other autoimmune (AI) disorders. However, a positive ANA…
Abstract Number: 1001 • ACR Convergence 2024
Perceived Mistreatment in Patients with Rheumatic Diseases: The Impact of the Underlying Diagnosis
Virginia Pascual Ramos¹, Guillermo Guaracha Basañez², Irazú Contreras-Yáñez³, Loraine Ledón-LLanes⁴, Ana Ortiz-Haro⁴ and Guillermo A Guaracha-Basañez⁴, ¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Federal District, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirón", Mexico City, Mexico, ³Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico city, Mexico, ⁴Instituto Nacional de Ciencias Medicas y Nutricion “Salvador Zubirán”, Mexico City, Distrito Federal, Mexico
Background/Purpose: Mistreatment is a complex problem that impacts people's quality of life, morbidity, and mortality. In aged people, it has been associated with female sex,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at abstracts@rheumatology.org.